Imperial College London
Alternate

Professor David Nutt DM, FRCP, FRCPsych, FSB, FMedSci

Faculty of Medicine, Department of Brain Sciences

The Edmond J Safra Chair in Neuropsychopharmacology
 
 
 
//

Contact

 

d.nutt

 
 
//

Location

 

Burlington Danes BuildingBurlington DanesHammersmith Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Daws:2021:rs.3.rs-513323/v1,
author = {Daws, R and Timmerman, C and Giribaldi, B and Sexton, J and Wall, M and Erritzoe, D and Roseman, L and Nutt, D and Carhart-Harris, R},
doi = {rs.3.rs-513323/v1},
title = {Decreased brain modularity after psilocybin therapy for depression.},
url = {http://dx.doi.org/10.21203/rs.3.rs-513323/v1},
year = {2021}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - <jats:title>Abstract</jats:title>        <jats:p><jats:bold>Importance </jats:bold>Psilocybin therapy shows antidepressant potential; our data link its antidepressant effects to decreased brain network modularity post-treatment. <jats:bold>Objective </jats:bold>To assess the sub-acute impact of psilocybin on brain activity in patients with depression. <jats:bold>Design </jats:bold>Pre vs post-treatment resting-state functional MRI (fMRI) was recorded in two trials: 1) Open-label treatment-resistant depression (TRD) trial with baseline vs 1 day post-treatment fMRI (April-2015 to April-2016); 2) Two-arm double-blind RCT in major depressive disorder (MDD), fMRI baseline vs 3 week after psilocybin-therapy or 6 weeks of daily escitalopram (January-2019 to March-2020).  <jats:bold>Setting </jats:bold>Study visits occurred at the NIHR Imperial Clinical Research Facility.<jats:bold>Participants </jats:bold>Adult male and female patients with TRD or MDD.  <jats:bold>Intervention(s) (for clinical trials) or Exposure(s) (for observational studies)</jats:bold>Study 1: Two oral doses of psilocybin (10mg and 25mg, fixed order, 7 days apart). fMRI was recorded at baseline and one day after the 25mg dose. Study 2: either: 2 x 25mg oral psilocybin, 3 weeks apart, plus 6 weeks of daily placebo (‘psilocybin-arm’), or 2 x 1mg oral psilocybin, 3 weeks apart, plus 6 weeks of daily escitalopram [10-20mg] (‘escitalopram-arm’). fMRI was recorded at baseline and 3 weeks after the 2nd psilocybin dose, which was the final day of the 6-week daily capsule ingestion.  <jats:bold>Main Outcome(s) and Measure(s) </jats:bold>Beck Depression Inventory and fMRI network modularity. <jats:bold> </jats:bold><jats:bold>Results </jats:bold>Study 1: In 16 adults (mean age [SD], 42.8 [10.1] years, 4 [25%] female), psilocybin therapy<jats:underline> </ja
AU  - Daws,R
AU  - Timmerman,C
AU  - Giribaldi,B
AU  - Sexton,J
AU  - Wall,M
AU  - Erritzoe,D
AU  - Roseman,L
AU  - Nutt,D
AU  - Carhart-Harris,R
DO  - rs.3.rs-513323/v1
PY  - 2021///
TI  - Decreased brain modularity after psilocybin therapy for depression.
UR  - http://dx.doi.org/10.21203/rs.3.rs-513323/v1
ER  -
Download